Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=eb2c98ba-03e0-4233-a110-a3f8c089cd44&Preview=1
Date 5/24/2010
Company Name NormOxys
Mailing Address 16 Laurel Ave. Wellesley, MA 02481
Company Description NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body’s ability to deliver oxygen more efficiently to diseased tissues with oxygen deficiency. This new class of drugs can be potentially developed in a broad range of clinical indications where therapeutic benefit can be obtained through an increased, regulated delivery of oxygen to hypoxic tissues, such as cancer, cardiovascular diseases, anemia, stroke and diabetic retinopathy.
Proceeds Purposes Proceeds from the financing will enable NormOxys to advance its lead drug candidate, OXY111A, into clinical development in 2010 in two diseases, chronic heart failure and cancer, and complete clinical studies through proof-of-concept in both of these indications.
